Literature DB >> 10047463

Flow cytometry study of human cyclin B1 and cyclin E expression in leukemic cell lines: cell cycle kinetics and cell localization.

J F Viallard1, F Lacombe, M Dupouy, H Ferry, F Belloc, J Reiffers.   

Abstract

Experiments by flow cytometry (FCM) after nuclei isolation have never been done to investigate cyclins. We have conducted different experiments by FCM using whole cells and isolated nuclei to study the immunolocalization and kinetic patterns of cyclin B1 and cyclin E in various leukemic cell lines. During asynchronous growth, all whole cells had a scheduled, cell cycle phase-restricted expression of cyclin B1. By using a washless immunostaining of unfixed nuclei, cyclin B1 was detected in all cell cycle phases, including G1, although to a lesser extent than in G2/M, suggesting that in whole cells the cyclin B1 epitope is masked and accessible only in isolated nuclei. When the cells were synchronized at the G1/S boundary by thymidine or in the G1 phase by sodium n-butyrate, an identical accumulation of cyclin B1 was observed. As for cyclin E, its expression was higher with thymidine treatment than with sodium n-butyrate, particularly in nuclei. The elevated cyclin B1 level in the cells arrested at the G1/S boundary may reflect the increased half-life of this protein stabilized as the result of cyclin E overexpression. However, our FCM data also support the notion that accumulation of human cyclin B1 in leukemic cell lines begins during the G1 phase of the cell cycle, probably in the nucleus. The detection of cyclin B1 by Western blot in cells sorted in the G1 phase of the cell cycle confirms this finding. It is possible, therefore, that tumor transformation or leukemic phenotype may invariably be associated with altered cyclin B1 expression. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10047463     DOI: 10.1006/excr.1998.4352

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  8 in total

1.  In vitro growth inhibition of human cancer cells by novel honokiol analogs.

Authors:  Jyh Ming Lin; A S Prakasha Gowda; Arun K Sharma; Shantu Amin
Journal:  Bioorg Med Chem       Date:  2012-04-03       Impact factor: 3.641

2.  A mathematical model of subpopulation kinetics for the deconvolution of leukaemia heterogeneity.

Authors:  María Fuentes-Garí; Ruth Misener; David García-Munzer; Eirini Velliou; Michael C Georgiadis; Margaritis Kostoglou; Efstratios N Pistikopoulos; Nicki Panoskaltsis; Athanasios Mantalaris
Journal:  J R Soc Interface       Date:  2015-07-06       Impact factor: 4.118

3.  Phosphorylation of HOX11/TLX1 on Threonine-247 during mitosis modulates expression of cyclin B1.

Authors:  Edwin Chen; Xiaoyong Huang; Yanzhen Zheng; You-Jun Li; Alden Chesney; Yaacov Ben-David; Eric Yang; Margaret R Hough
Journal:  Mol Cancer       Date:  2010-09-16       Impact factor: 27.401

4.  The new isothiocyanate 4-(methylthio)butylisothiocyanate selectively affects cell-cycle progression and apoptosis induction of human leukemia cells.

Authors:  Carmela Fimognari; Michael Nüsse; Renato Iori; Giorgio Cantelli-Forti; Patrizia Hrelia
Journal:  Invest New Drugs       Date:  2004-04       Impact factor: 3.850

5.  Dynamic expression profiles from static cytometry data: component fitting and conversion to relative, "same scale" values.

Authors:  Jayant Avva; Michael C Weis; R Michael Sramkoski; Sree N Sreenath; James W Jacobberger
Journal:  PLoS One       Date:  2012-07-12       Impact factor: 3.240

6.  Growth dynamics and cyclin expression in cutaneous T-cell lymphoma cell lines.

Authors:  Edyta Biskup; Valentina Manfé; Maria R Kamstrup; Robert Gniadecki
Journal:  Dermatol Reports       Date:  2010-05-06

7.  Cell cycle-related cyclin b1 quantification.

Authors:  Phyllis S Frisa; James W Jacobberger
Journal:  PLoS One       Date:  2009-09-18       Impact factor: 3.240

8.  A data-driven, mathematical model of mammalian cell cycle regulation.

Authors:  Michael C Weis; Jayant Avva; James W Jacobberger; Sree N Sreenath
Journal:  PLoS One       Date:  2014-05-13       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.